Ashley Dombkowski

Co-Founder and CEO

Ashley Dombkowski, Ph.D. is Co-Founder and CEO of BEFORE Brands™, a consumer-focused product platform focused on health and wellness for parents and families. She co-founded the company in 2015 with Dr. Kari Nadeau, the Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. She has 20 years of experience as an operating executive, entrepreneur, and investor in fields spanning consumer health and life sciences. Her portfolio of innovative biotechnology, medical device, consumer health and HCIT companies has included 23andMe, Adolor, Alnara, BioVitrum, Epizyme, iPierian, Neosil, Nevro, Rigel, Tercica, and Twist. She previously served as a Managing Director with Bay City Capital, a $1.6B venture capital firm. Prior to that she served as Chief Business Officer and Vice President of Operations for 23andMe, where she oversaw the company’s finance and operations activities and had responsibility for the company’s long term business strategy. Before to joining 23andMe, she was a Managing Director with MPM Capital where she served as a member of the firm’s Investment Committee. Prior to this, she was an Equity Analyst for hedge fund Tiger Management L.L.C. and for institutional asset management firm Dresdner RCM Global Investors. Dr. Dombkowski holds a Ph.D. in Mathematics from Rice University and received her B.A. in Mathematics from Wellesley College. She has been widely quoted in publications ranging from Nature to The Wall Street Journal and she has appeared in media outlets including CNBC, SXSW, and TedMed. She was recognized as one of the 100 Most Influential Women in Business by the San Jose/Silicon Valley Business Journal in 2010. She is a member of the Board of Directors of USA Volleyball, the National Governing Body for all disciplines of Volleyball as recognized by the U.S. Olympic Committee, and serves as Chair of the Audit, Finance, and Budget committee.

Chris Cornyn

Chief Innovation Officer

Chris is the Chief Innovation Officer of BEFORE Brands™ and is responsible for all Product and Brand Development for the company. Chris was formerly the Chief Innovation Officer for Revolution Foods, a company that creates delicious foods to improve the health and wellbeing of students and families across the United States. Chris and his team led new product innovations, new services, new products, and new brands to further the growth of the Revolution mission. Chris was the founder of DINE, The Food & Drink Agency which was created to help food entrepreneurs launch and promote disruptive new food brands. In 2011, Chris sold DINE to Mattson, the largest independent food and beverage innovation company in the country. During his tenure, Chris and his team launched over 20 new food brands with 60+ SKUs. Chris began his branding and marketing career working with Klondike Ice Cream Bars, Betty Crocker and Yoplait Frozen Yogurt. Chris is a frequent speaker and featured contributor to business and food publications. He co-starred as one of the celebrity mentors on the Lifetime TV show "Supermarket Superstar."

Marc Chapman

Chief Operating Officer

Marc is the Chief Operating Officer for BEFORE Brands™ where he leads the company’s e-Commerce operations, Manufacturing, Supply Chain, IT and Support functions.  Marc is a seasoned technology executive with a broad range of experiences with businesses at all levels of maturity and size. His background includes enterprise (Kodak, Intel, Hewlett Packard) and early stage companies (Snapfish, Minted, Symphony Commerce) spanning Direct to Consumer (D2C) and Business to Business (B2B) economic models. He was a founding employee and member of the executive management team responsible for building and guiding it from conception to purchase by HP in 2005 for $300M.  Most recently, he was Chief Operating Officer of Symphony Commerce,  a SaaS technology platform providing commerce and fulfillment software to small and medium sized businesses.  Prior to that, he was Chief Operating Officer for, an online marketplace comprised of independent artists who sell their designs on printed and digital products.  Marc has also held finance and strategy roles with both Eastman Kodak Company and Intel Corporation.

Ben Thomander

Ben Thomander

VP Finance

Ben is the VP of Finance for BEFORE Brands where he leads the company's finance, accounting, and treasury activities.  Previously Ben served as Controller for 23andMe, Inc., the leading personal genetics company, and as Treasurer of the 23andMe Research Institute. Prior to 23andMe, Ben worked at Connor Group in its Technical Accounting and IPO Services practice where he assisted technology companies with complex revenue recognition issues and IPO filings. Prior to Connor Group, Ben worked as a Manager at PricewaterhouseCoopers in San Jose, in the Life Science and Venture Capital Group, providing audit and assurance services to various public and privately held companies in the pharmaceutical, biotechnology, and medical device spaces. Ben holds a Bachelor of Science degree in Accounting from Brigham Young University and is a Certified Public Accountant.

Kunjal Raheja

Kunjal Raheja

Director of Supply Chain

Kunjal is the Director of Supply Chain for BEFORE Brands™ where he is responsible for overseeing the Manufacturing, Supply chain and Fulfillment efforts for the company. Kunjal's background is in industries that involve extensive operations. His roles have spanned fulfillment, customer support, product management and program management in companies ranging from early-stage startups to large enterprises. Kunjal most recently served as the Head of Fulfillment at Symphony Commerce where his team managed e-commerce operations for brands like Gatorade, FIJI, Neff, and Jbrand. He has previously led global projects across R&D, marketing and technical sales for Microsoft’s automotive division as well as revenue management and new business development for Hotwire’s flight division.

Kari Nadeau

Co-Founder and Inventor

Kari Nadeau, M.D., Ph.D. is the Director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. Her center’s vision is to find the causes and cures of allergies. Her center’s mission is to transform the lives of patients and families through innovative science and compassionate care.

After graduating from Haverford College (summa cum laude) with a degree in biology, Dr. Nadeau attended Harvard Medical School via the Medical Scientist Training Program (NIH), and received a PhD in Biological Chemistry and Molecular Pharmacology and an MD in 1995. She then performed an internship and residency in pediatrics at the Children’s Hospital Boston, Harvard Medical School. From 1998 to 2002, she worked in the field of biopharmaceuticals and led clinical research to obtain FDA approval for two biologics in the field of Autoimmunity and Oncology, respectively. From 2003-2006, Dr. Nadeau was a fellow in Asthma, Allergy and Immunology at the Stanford/UCSF program under Dr. Umetsu. During this time, she also did a postdoctoral fellowship in human immune tolerance mechanisms in asthma and allergy. In 2006, Dr. Nadeau was appointed to the Stanford University School of Medicine with appointments in Pediatrics and Otolaryngology. She enjoys mentoring students, post doctoral candidates, and faculty. She currently holds an endowed faculty position under the Naddisy Family Foundation. Dr. Nadeau has served as a reviewer for NIH Study Sections, and a member of the American Lung Association Medical Board, CA.  She serves on the Environmental Health Policy committee for the American Thoracic Society and is a Fellow in the American Academy of Allergy, Asthma and Immunology and is a member of ASCI (American Society of Clinical Investigation). She has authored or co-authored more than 110 original papers, and has maintained an interest in the study of immune mechanisms in allergy and asthma for more than 20 years. Her laboratory focuses on the study of immunological mechanisms involved in the cause, diagnosis, and therapy for allergy and asthma.  

Ruchi Gupta

Sr. Medical Advisor

Ruchi Gupta, M.D., M.P.H. has more than 15 years of experience as a board-certified pediatrician and health researcher. She completed her undergraduate and medical education at the University of Louisville. She completed her medical residency at Children's Hospital & Regional Medical Center, University of Washington in Seattle, WA and then a pediatric health services research fellowship at Boston Children's Hospital and Harvard Medical School. Finally, she received her Masters of Public Health from the Harvard School of Public Health. She is nationally recognized for her groundbreaking research in the area of food allergy epidemiology; specifically her research on childhood food allergy prevalence. She has also significantly contributed to academic research surrounding economic costs, pediatric management of food allergy, ED visits and hospitalizations, quality of life and use of epinephrine in schools. Dr. Gupta has been a faculty member at Northwestern Medicine since 2004 and a clinical attending at the Ann & Robert H. Lurie Children's Hospital of Chicago where she is actively involved in clinical, epidemiological, and community research. Dr. Gupta leads the Food Allergy Outcomes Research Program and is a co­founder of the Food Allergy Research Consortium at Northwestern Medicine. She is also the author of the book The Food Allergy Experience. Dr. Gupta has over 60 publications and her work has been featured in major TV networks and print media

George Montgomery

Board Member

George Montgomery is a Partner with Gurnet Point Capital and has more than 25 years of experience in healthcare entrepreneurship, investment banking, and venture investing. He is an experienced operating executive, having served as CFO for Coherus BioSciences where he oversaw all finance and business development activities for the company. He previously served as a Managing Director at Sagent Advisors, LLC. and as a Managing Director at Montgomery& Co., LLC where he led the firm’s healthcare effort and helped open their SanFrancisco office. During his tenure at Montgomery & Co, he served on the firm’s Board of Directors and was a member of the executive committee. Prior to Montgomery & Co., he was a Managing Director at JP Morgan H&Q where he led the firm’s healthcare efforts on the West Coast. He has also been a Managing Director at Cowen & Company and started his career at Credit Suisse First Boston in 1983. George received his MBA from the Wharton School at the University of Pennsylvania and his BA fromYale College.

Greg Horn

Board Member

Greg Horn is a leading innovator in health and nutrition business, with two decades of experience in developing and managing companies associated with personal health, nutrition and environmental sustainability. Greg is CEO of Specialty Nutrition Group, Inc. a development firm focused on commercializing nutrition innovation.  He has co-founded and managed several branded nutrition and healthy living companies, including Celsius®, Brand New Brands, Attune Foods, Pronutria Biosciences (now Axcella Health), WikiFoods and Nutrition Capital Network. He is former CEO of both Garden of Life, currently the top nutrition brand in the natural channel and General Nutrition Centers (GNC), the world’s largest specialty retailer of nutrition products, which added $100 million per year to profitable revenue for eleven years in a row during his tenure in management. Greg is the best-selling author of Living Green (2005), Living Well (2016), the co-author or The Meaning of Light and co-founder of Eco Shoppe. Greg holds an MBA from UCLA and a BA (summa cum laude, phi beta kappa) from the University of Redlands.

Christopher A. Viehbacher

Board Member

Chris Viehbacher is the Managing Partner of Gurnet Point Capital. Gurnet Point is a Boston based investment fund associated with the Bertarelli family and has a $ 2 billion capital allocation. He is also a member of the Board of Pure Tech Health plc and is the Chairman of Vedanta, a Pure Tech portfolio company. He is a member of the Board of Trustees of Northeastern University


Chris is the former CEO and Member of the Board of Directors of Sanofi, a Fortune 50 Biopharmaceutical company based in Paris. He was also the Chairman of the Board of Genzyme in Boston.

Prior to joining Sanofi, Chris spent 20 years with GlaxoSmithKline in Germany, Canada, France and, latterly, the US as President of GSK North America. He was a Member of the Board of Directors of GSK plc in London and Co-President of GSK’s Portfolio Management Board. Chris began his career with Price Waterhouse after graduating with a degree in Commerce at Queen/s University in Canada.

Chris has been a strong advocate for the healthcare industry. Current and past advocacy roles include:

Former Co-chair with Bill Gates, the CEO Roundtable on Neglected Diseases

Past-Chairman of the CEO Roundtable on Cancer. Chairman of the Board of the Pharmaceutical Research and Manufacturers of America in Washington

President of the European Federation of Pharmaceutical Industries and Associations in Brussels.

Chair of the Health Governors at World Economic Forum and Co-chair of a WEF initiative to create a Global Charter for Healthy Living.

Member of the International Business Council.

Chris has in the past served on various advisory groups at MIT, Duke University and Queen’s University at Kingston, Ontario.

Chris has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide. He has also received France’s highest civilian honor, the Legion d’Honneur.


Kimberly Yates

Community Specialist

Kim is the Special Advisor to Kari Nadeau and Public Relations Officer at the Sean N. Parker Center for Allergy and Asthma Research at Stanford University. She has partnered with Kari for the past 8 years working tirelessly to make the creation of the Center possible as well as ensure the research, therapies and diagnostics are publicized and have the resources necessary to come to fruition. As the parent of the first Multi Allergen Oral Immunotherapy patient she also serves as an ambassador throughout the country for the Center and the treatments being done at Stanford. Her leadership bridges philanthropy, community outreach and support and communications to make the Center’s vision a reality.